Market Place
Sourcing Support
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter
05 Jan 2021 //
PRNEWSWIRE
Therapix Biosciences to Collaborate with The University of Calgary THX-160
02 Dec 2020 //
PRNEWSWIRE
Therapix Biosciences to Collaborate with The University of Calgary
02 Dec 2020 //
PRNEWSWIRE
Therapix Biosciences Issues CEO Letter to its Shareholders
30 Nov 2020 //
PRNEWSWIRE
Therapix Biosciences Announces Replacement of its Board of Directors
21 Aug 2020 //
PRNEWSWIRE
Therapix Biosciences Announces OTC Pink Ticker Symbol `TRPXY` and Removal
09 Jul 2020 //
PRNEWSWIRE
Therapix Announces OTC Pink Ticker Symbol `TRPXY` and Removal of Injunction
08 Jul 2020 //
PRNEWSWIRE
Therapix Biosciences Receives Notice of Delisting and Injunction Israeli Court
30 Jun 2020 //
PRNEWSWIRE
Therapix Biosciences Raises $2.6 Million in Private Placement
29 Jun 2020 //
PRNEWSWIRE
Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication
19 May 2020 //
PR NEWSWIRE
Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance
28 Apr 2020 //
PR NEWSWIRE
Therapix Biosciences Announces Appointment of New CEO
22 Apr 2020 //
PR NEWSWIRE
Therapix Biosciences Announces Pricing of $1.25 Million Public Offering
01 Apr 2020 //
PR NEWSWIRE
Therapix Biosciences Ltd. Signs Securities Purchase Agreement
19 Mar 2020 //
PRNEWSWIRE
Therapix Announces the Continued Development of THX-210 ("RESPECTRUM")
02 Dec 2019 //
PR NEWSWIRE
Therapix Biosciences Enters Into MOU With Heavenly Rx, Ltd.
18 Nov 2019 //
PR NEWSWIRE
Therapix Biosciences Announces +ve Topline Results From PhIIa Trial of THX-110
13 Nov 2019 //
PR NEWSWIRE
Therapix & Destiny Biosciences Global Mutually Decide to Discontinue Negotiation
07 Nov 2019 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.